Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use

Since 2006, combined graft-versus-host disease (GVHD) prophylaxis with ATG Grafalon has been our department’s base of peri-transplant supportive care. This recent retrospective study included 398 patients who underwent their first allogeneic hematopoietic stem cell transplantation after receiving a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovacsova, Flora, Folber, Frantisek, Weinbergerova, Barbora, Stepanova, Radka, Kabut, Tomas, Tomiska, Miroslav, Krejci, Marta, Mayer, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640449/
https://www.ncbi.nlm.nih.gov/pubmed/37783854
http://dx.doi.org/10.1007/s00277-023-05479-w
Descripción
Sumario:Since 2006, combined graft-versus-host disease (GVHD) prophylaxis with ATG Grafalon has been our department’s base of peri-transplant supportive care. This recent retrospective study included 398 patients who underwent their first allogeneic hematopoietic stem cell transplantation after receiving a defined dose of ATG Grafalon. Our observations recorded reduced incidence of severe acute and chronic GVHD without negative impact on overall survival in a nonselected group with standard and uniform GVHD prophylaxis.

Ejemplares similares